Display options
Cite
Patel N, Able S, Allen D, et al. Monitoring response to anti-angiogenic mTOR inhibitor therapy in vivo using . EJNMMI Res. 2017;7(1):49doi: 10.1186/s13550-017-0297-9.
Patel, N., Able, S., Allen, D., Fokas, E., Cornelissen, B., Gleeson, F. V., Harris, A. L., & Vallis, K. A. (2017). Monitoring response to anti-angiogenic mTOR inhibitor therapy in vivo using . EJNMMI research, 7(1), 49. https://doi.org/10.1186/s13550-017-0297-9
Patel, Neel, et al. "Monitoring response to anti-angiogenic mTOR inhibitor therapy in vivo using ." EJNMMI research vol. 7,1 (2017): 49. doi: https://doi.org/10.1186/s13550-017-0297-9
Patel N, Able S, Allen D, Fokas E, Cornelissen B, Gleeson FV, Harris AL, Vallis KA. Monitoring response to anti-angiogenic mTOR inhibitor therapy in vivo using . EJNMMI Res. 2017 Dec;7(1):49. doi: 10.1186/s13550-017-0297-9. Epub 2017 May 30. PMID: 28560583; PMCID: PMC5449352.
Copy Download .nbib Format: NLM
Share it on

EJNMMI Res. 2017 Dec;7(1):49. doi: 10.1186/s13550-017-0297-9. Epub 2017 May 30.

Monitoring response to anti-angiogenic mTOR inhibitor therapy in vivo using .

EJNMMI research

Neel Patel, Sarah Able, Danny Allen, Emmanouil Fokas, Bart Cornelissen, Fergus V Gleeson, Adrian L Harris, Katherine A Vallis

Affiliations

  1. Department of Radiology, Churchill Hospital, Headington, OX3 7LE, Oxford, UK. [email protected].
  2. CRUK/MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, UK. [email protected].
  3. CRUK/MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, UK.
  4. Department of Radiology, Churchill Hospital, Headington, OX3 7LE, Oxford, UK.
  5. Department of Oncology, University of Oxford, Oxford, UK.

PMID: 28560583 PMCID: PMC5449352 DOI: 10.1186/s13550-017-0297-9

[No abstract available.]

Keywords: Angiogenesis; Bevacizumab; Cancer; Radionuclide; Rapamycin

References

  1. Clin Cancer Res. 2012 Nov 15;18(22):6306-14 - PubMed
  2. Cancer Res. 2011 Mar 1;71(5):1573-83 - PubMed
  3. PLoS One. 2012;7(8):e42913 - PubMed
  4. Biomaterials. 2013 Jan;34(4):1146-54 - PubMed
  5. Nat Med. 2002 Feb;8(2):128-35 - PubMed
  6. J Nucl Med. 2007 Aug;48(8):1313-9 - PubMed
  7. J Nucl Med. 2010 May;51(5):761-7 - PubMed
  8. Nat Med. 1995 Jan;1(1):27-31 - PubMed
  9. Cancer Res. 2012 Jan 1;72(1):239-48 - PubMed
  10. Cancer Biother Radiopharm. 2009 Dec;24(6):637-47 - PubMed
  11. J Clin Oncol. 2005 Feb 10;23(5):1011-27 - PubMed
  12. Int J Cancer. 2008 May 15;122(10 ):2310-4 - PubMed
  13. Eur J Cancer. 1998 Dec;34(13):2041-5 - PubMed
  14. Cancer Biother Radiopharm. 2009 Apr;24(2):195-200 - PubMed
  15. Endocr Rev. 1997 Feb;18(1):4-25 - PubMed
  16. Nat Clin Pract Neurol. 2007 Dec;3(12 ):682-93 - PubMed
  17. Cancer Res. 1997 Oct 15;57(20):4593-9 - PubMed
  18. J Nucl Med. 2010 Nov;51(11):1707-15 - PubMed
  19. Eur J Cancer. 2008 Sep;44(13):1835-40 - PubMed
  20. Eur J Cancer. 2000 Apr;36(6):748-53 - PubMed
  21. Cancer Sci. 2011 Jan;102(1):117-21 - PubMed
  22. N Engl J Med. 2008 May 8;358(19):2039-49 - PubMed
  23. Semin Oncol. 2013 Aug;40(4):444-58 - PubMed
  24. J Clin Invest. 2008 Sep;118(9):3065-74 - PubMed
  25. Mol Cancer Ther. 2014 Nov;13(11):2477-88 - PubMed
  26. Nat Rev Drug Discov. 2011 Jun;10(6):417-27 - PubMed
  27. Int J Cancer. 2011 Feb 15;128(4):920-6 - PubMed
  28. Br J Cancer. 2008 Apr 22;98(8):1366-79 - PubMed
  29. Invest Ophthalmol Vis Sci. 2011 Jul 29;52(8):5899-903 - PubMed
  30. Cancer Metastasis Rev. 2007 Dec;26(3-4):611-21 - PubMed
  31. Radiat Oncol. 2012 Mar 27;7:48 - PubMed
  32. J Hepatol. 2008 Jul;49(1):52-60 - PubMed
  33. Eur J Cancer. 2011 Jul;47(10):1595-602 - PubMed
  34. J Nucl Med. 2014 Jul;55(7):1087-92 - PubMed
  35. J Biol Chem. 2006 Jan 13;281(2):951-61 - PubMed
  36. Nat Rev Cancer. 2002 Oct;2(10):795-803 - PubMed

Publication Types

Grant support